14 12, 2024

General Anesthesia for Cesarean Deliveries Show Link to Postpartum Depression

By |2024-12-14T12:57:37-08:00December 14th, 2024|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

According to a brief on Medscape, supported by the NIH, The use of general anesthesia during cesarean deliveries is associated with an increased risk for postpartum depression (PPD) that necessitates hospitalization as well as a risk for suicidality, regardless of obstetric complications. Researchers conducted a retrospective cohort study to assess [...]

13 12, 2024

First Episode Psychosis in a Teen with Narcolepsy and Cataplexy

By |2024-12-13T12:28:47-08:00December 13th, 2024|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

Writing in Psychopharmacology Bulletin, Trishna Sharma, Annette C. Kestner and Abhishek Reddy described a 17-year-old female with a history of NT1 and no past psychiatric history presented to the hospital from the community due to a psychotic episode of unknown etiology. During this event, she was told by “the Lord” [...]

13 12, 2024

Complete Resolution of Catatonia Following a Single Intravenous Lorazepam Challenge Test: An Early Intervention in Psychosis Case Report

By |2024-12-13T12:31:08-08:00December 13th, 2024|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

Writing in Psychopharmacology Bulletin, authors Chinenye Okoro, Kaye Homer, Marlene Kelbrick, Jonny Walker, Mary Sam, Justine Burge, Rosie Richards, Gabriela Paduret, and Feras Ali Mustafa examined a 53-year-old Caucasian female who had been under the care of the early intervention for psychosis (EIP) service following a first episode psychosis. At [...]

13 12, 2024

Early Positive Report of Viloxazine for a Child with Hyperkinetic Autism

By |2024-12-13T12:34:05-08:00December 13th, 2024|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

Ahmed Naguy, Nadyah Alayadhi, Saxby Pridmore, Bibi Alamiri, writing in Psychopharmacology Bulletin, made the following observations: An 11-year-old male Qatari boy was brought in to hospital by his parents for episodic behavioural dyscontrol. He was a known case of essential Autism spectrum disorder (ASD) with mild intellectual disability (FSIQ = [...]

22 06, 2023

Crisis lines testing AI to help review response

By |2023-06-22T09:46:04-07:00June 22nd, 2023|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

Crisis support lines are currently undergoing testing of artificial intelligence (AI) to assess the quality of their response. These support lines rely on well-trained counselors who are adept at handling sensitive conversations, particularly those involving potential suicide. However, the process of reviewing randomly selected recordings to ensure quality control is [...]

10 05, 2023

New APA Study Shows a Spike in Anxiety Among a Large Swath of America

By |2023-05-10T14:11:20-07:00May 10th, 2023|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

According to the American Psychiatric Association's annual poll, 70% of adults in the United States report feeling anxious or extremely anxious about their own and their family's safety. This number is 6% higher than in the past two years, although lower than during the early stages of the pandemic in [...]

16 03, 2023

Neuromodulation Device for Depression Granted Designation from FDA

By |2023-03-16T13:04:04-07:00March 16th, 2023|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

According to published reports, The US Food and Drug Administration (FDA) has granted Breakthrough Device designation to Sooma Medical's portable, noninvasive neuromodulation device for treating depression, which can be administered by the patient. The device, which uses transcranial direct current stimulation to target specific areas of the brain and alleviate [...]

8 02, 2023

Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression

By |2023-02-08T08:34:35-08:00February 8th, 2023|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

Objective: To compare the efficacy and speed of achieving remission/response in treatment-resistant depression (TRD) patients treated with subanesthetic intravenous (IV) ketamine and intranasal (IN) esketamine approved by the US Food and Drug Administration (FDA). Methods: The study was observational and included 62 adults with TRD who received up to 6 [...]

2 02, 2023

Pimavanserin Shows Promise for MDD

By |2023-02-02T10:23:22-08:00February 2nd, 2023|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

In a phase 2 study, pimavanserin showed promise as a treatment for major depressive disorder (MDD) when used in combination with other antidepressants. Two phase 3 studies were then conducted to further evaluate its efficacy and safety in patients with MDD who had not responded well to existing antidepressant treatment. [...]

Go to Top